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Abstract: Piriformis muscle syndrome (PMS) is caused by prolonged or excessive 
contraction of the piriformis muscle associated with pain in the buttocks, hips, and lower 
limbs because of the close proximity to the sciatic nerve. Botulinum toxin type A (BoNT-A) 
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reduces muscle hypertonia as well as muscle contracture and pain inhibiting substance P 
release and other inflammatory factors. BoNT-A injection technique is important 
considering the difficult access of the needle for deep location, the small size of the 
muscle, and the proximity to neurovascular structures. Ultrasound guidance is easy to use 
and painless and several studies describe its use during BoNT-A administration in PMS.  
In the present review article, we briefly updated current knowledge regarding the BoNT 
therapy of PMS, describing also a case report in which this syndrome was treated with an 
ultrasound-guided injection of incobotulinumtoxin A. Pain reduction with an increase of 
hip articular range of motion in this patient with PMS confirmed the effectiveness of 
BoNT-A injection for the management of this syndrome. 
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1. Introduction 
The term “piriformis muscle syndrome” (PMS) identifies a condition of buttocks and posterior hip 
pain with limited articular range of motion (ROM) of the hip not caused by lumbar radiculopathies, but 
produced by prolonged or excessive contraction of the piriformis muscle. Subjects suffering from this 
syndrome refer a sciatic-like pain. This can be explained considering that proximal sciatic nerve can be 
compressed by the anatomical variations of the piriformis muscle itself or can be injured by the scar 
tissue of the piriformis muscle and adjacent tissues from trauma of the gluteal region or for pinching of 
sciatic nerve by the piriformis muscle during leg and hip maneuvers [1]. Several therapies can be used 
for pain relief with controversial results. Conservative strategies include hip extensor, abductor, and 
adductor muscle stretching exercises, massage, physical therapies (heat, ultrasound, laser therapy), and 
drug treatments (nonsteroidal anti-inflammatory drugs, analgesics, and muscle relaxants). If the  
conservative regimen fails, local injection of piriformis muscle, surgery and trigger-point injections 
with local anesthetic with or without corticosteroids should be performed into piriformis muscle [2].  
In recent years, several published studies showed the employment of botulinum toxin type A (BoNT-A) 
injection as a new therapeutic option to reduce buttocks and low back pain induced by PMS [3–6]. 
Botulinum toxin is actually the gold standard therapy in the management of focal hypertonia by 
blocking the release of acetylcholine at the neuromuscular junctions in the injected muscle and 
resulting in a reduction of spasticity, dystonia, and related disorders [7,8]. Moreover, BoNT-A has 
been shown to reduce muscle pain with safety and effectiveness [9–12]. Muscle pain can result from 
ischemic, thermal, or mechanical stimulation and it is usually described as aching or cramping and it is 
often difficult to precisely localize. The list of factors known to sensitize muscular nociceptors 
includes bradykinins, serotonin, potassium, prostaglandin E2 and a variety of neuropeptides, such as 
substance P and the neuropeptide calcitonin gene-related peptide (CGRP). BoNT-A has been found to 
inhibit substance P release from cultured embryonic dorsal root ganglion neurons and to reduce 
stimulated (but not basal) release of CGRP from cultured trigeminal ganglia neurons. Based on these 
results, BoNT-A may inhibit the release of these neuropeptides in vivo, which may account for its 
beneficial effects on pain [13–15]. Moreover, the concentrations and release patterns of the sensitizing 
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mediators may respond directly to the reduction of excessive contractions or spasms evoked by 
botulinum toxin reducing also the increase of lactate in the contracted muscle causing of muscle pain. 
In the present review article, we briefly reviewed current knowledge about the employment of BoNT-A for 
the treatment of PMS, also describing a case report about its use with an ultrasound-guided injection  
technique for the management of this syndrome. 
2. Methods 
In the present article, we reviewed existing literature about the use of BoNT-A in the treatment of 
PMS, including randomized placebo-controlled studies, double-blind trials, case-reports, and  
meta-analyses published in the period from December 1989 to July 2014. We chose this starting date 
for our literature search because in December 1989, BoNT-A was approved by the US Food and Drug 
Administration for the treatment of strabismus, blepharospasm, and hemifacial spasm in patients over 
12 years old. This narrative review was based upon searches of the US National Library of Medicine 
(PubMed), Ovid MEDLINE, EMBASE, Google Scholar, Web of Science, and Scopus databases using 
combinations of the following terms to identify the type of treatment (piriformis muscle  
syndrome OR PMS and botulinum toxin AND piriformis muscle syndrome OR PMS treated with 
botulinum toxin) combined with terms to determine the area of interest (muscle pain OR myofascial 
pain OR myofascial pain syndrome). A search filter was developed to include only human studies. 
There were no language restrictions on the search. The references of each study selected were screened 
to identify studies that were not included on the electronic search. Key textbooks were also searched in 
addition to the electronic database search. References mentioned in the textbooks were likewise  
reviewed. From 32 articles identified with multiple electronic searches, we screened titles and abstracts 
of the citations downloaded from the searches identifying 16 potential relevant articles chosen for a 
closer review. Excluding the other five articles that did not meet the inclusion criteria, we  
obtained full copies of the 11 potentially suitable reports for further assessment. After inclusion  
of one article of interest from the reference lists of the selected articles and exclusion of other  
three articles, nine studies met study eligibility criteria, and were finally included in the overall  
review [3,4,6,16–21] (Table 1). 
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Table 1. Key and reviewed studies on the employment of botulinum toxin type A (BoNT-A) and type B (BoNT-B) therapy in the treatment of 
piriformis muscle syndrome (PMS). 
First author and 
year of publication 
Study design 
Number of 
patients with PMS
Doses (U) and number of 
injections 
Injection 
guide 
Outcome 
measures 
Adjunctive therapy Clinical results/adverse effects 
Fanucci et al.,  
2001 [4] 
Prospective 30 
OnabotulinumtoxinA 100 U:  
26 received one injections  
4 received two injections 
CT 
Not specific 
pain score 
Not indicated 
Reduction of pain intensity after 5–7 days for 26 subjects; 
other 4 subjects reported a complete pain reduction in the 
following week/No adverse effects 
Fishman et al.,  
2002 [17] 
RCT double-blind, 
parallel 
21 AbobotulinumtoxinA 200 U EMG VAS 
Twice-weekly physical 
therapy program 
65% of the patients reported a 50% of pain reduction/No 
adverse effects 
Childers et al.,  
2002 [3] 
RCT double-blind, 
crossover 
9 OnabotulinumtoxinA 100 U FL EMG VAS Not indicated 
Reduction of pain intensity, distress, spasm and interference 
with activities respect to baseline/No adverse effects 
Fishman et al.,  
2004 [20] 
Prospective 27 BoNT-B 12,500 U EMG VAS 
Physical therapy twice 
weekly for 3 months 
A total of 24 of 27 study patients had a pain relief of 50%. 
The most severe adverse effects were dry mouth and 
dysphagia, approaching 50% of patients at 2 and 4 weeks 
Lang et al.,  
2004 [21] 
Prospective 20 BoNT-B 5,000 U EMG VAS 
Dry mouth was reported 
in 6 of 20 patients 
Reduction of myofascial buttock and hip pain  
associated with PMS/No adverse effects 
Yoon et al.,  
2006 [6] 
Prospective 20 
AbobotulinumtoxinA  
150 U:  
One injection 
CT 
NRS at 4, 8, 
12 weeks 
Korean  
SF-36 
Stretching exercise 
20 times/day for  
12 week 
Pain reduction respect to baseline(p < 0.0001) Improvement 
of physical functioning, role physical, bodily pain, general 
health, vitality and social functioning/Mild and transient 
adverse events (one case of flu-like syndrome lasting 2 days, 
five cases of worsening muscular pain lasting 2–3 days,  
one patient had ecchymosis in the lower limb for 2 days,  
two patients had atrophy of the piriformis muscle, one case 
of transient numbness lasting no longer than 72 h 
Michel et al.,  
2013 [16] 
Prospective 122 
OnabotulinumtoxinA Ranged 
between 50 and 100 U:  
51 received one Injection;  
43 received two injections;  
18 received three injections;  
9 received four injections;  
1 received five injections 
EMG VAS Not indicated 
“Very good’ or ‘Good” in 77% of  
the cases “Average” in 7.4% of  
the cases “Poor” in 15.6% of  
the cases/No adverse effects 
Fabregat et al.,  
2014 [18] 
Feasibility study 10 OnabotulinumtoxinA 100 U US Not indicated Not indicated No adverse effects during the BoNT-A injections 
Al-Al-Shaikh et al., 
2015 [19] 
Retrospective 12 OnabotulinumtoxinA 100 U US CT VAS Not indicated 
Buttock and sciatic pain reduction respect to baseline  
(p < 0.001)/No adverse effects 
CT: Computed Tomography; RCT: Randomized Clinical Trial; EMG: Electromyography; VAS: Visual Analogue Scale; FL: Fluoroscopy; NRS: Numeric Rating Scale; SF-36: 36-Item Short Form Health Survey; US: Ultrasound. 
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3. Botulinum Toxin in Piriformis Muscle Syndrome 
Many studies described the use of botulinum toxin for reducing muscle and myofascial pain, but 
there are only few reports about the treatment of PMS [3,4,6,16–21] (Table 1). One of the first studies 
showing the use of BoNT-A was conducted by Fanucci and colleagues on thirty subjects suffering 
from PMS and treated with onabotulinumtoxin A [4]. The authors referred to have treated with  
100 units (U)/1 mL of saline, under computed tomographic (CT) guidance using a 20 G needle.  
No complications or adverse reaction were reported. Among the treated subjects, 26 subjects referred  
a gradual relief of symptoms after 5–7 days, whereas 4 subjects needed another CT-guided injection of 
100 U/2 mL onabotulinumtoxin A resulting a complete pain reduction in the following week [4].  
The efficacy of onabotulinumtoxin A 100 U compared to saline solution was examined in a double-blind, 
single group study. Nine women suffering from PMS received fluoroscopic/electromyography  
(EMG)-guided piriformis injections and visual analogue scale (VAS) was used to measure pain  
intensity, distress, spasm, and interference with activities. After injection with placebo, decreases of 
these symptoms were detected, but only in one of the four categories (distress) whereas after injection with  
BoNT-A decreases were observed under all VAS categories suggesting that 100 U of onabotulinumtoxin A 
can reduce pain to a greater extent than similar injections with saline solution alone [3]. 
Fishman and colleagues compared the efficacy of abobotulinumtoxin A 200 U (21 subjects),  
triamcinolone and lidocaine (31 subjects), and normal saline as placebo (15 subjects) used in  
conjunction with physical therapy for the treatment of PMS [17]. A 50% reduction in VAS scores was 
used as the main outcome. As measured on the VAS, patients injected with abobotulinumtoxin A 
(65%) experienced more relief from pain than patients receiving lidocaine with steroid (32%) and more 
relief than patients receiving placebo (6%). Authors concluded that treatment with abobotulinumtoxin A 
for PMS provided therapeutic effectiveness that is superior to steroid and to placebo [17]. 
In a prospective, single-site, open-label trial, 20 subjects with PMS were treated with 150 U of 
abobotulinumtoxin A in 3 mL of normal saline into the affected unilateral piriformis muscle using a  
CT-guidance [6]. After the injection each patient was given instructions to perform standard stretching 
exercises 20 times each day for 12 weeks after treatment. Outcome measures included a numeric rating 
scale for pain at baseline and at 4, 8, and 12 weeks after treatment. The Korean version of the 36-Item 
Short Form Health Survey (SF-36) was used to evaluate the health-related quality of life at baseline 
and at 4 weeks of treatment. The patients reported an important reduction of pain with an improvement 
of quality life in terms of physical functioning, role physical, bodily pain, general health, vitality, and 
social functioning [6]. Only mild and transient adverse events were reported (one case of flu-like  
syndrome lasting two days, five cases of worsening muscular pain lasting 2–3 days, one patient had  
ecchymosis in the lower limb for two days, two patients had atrophy of the piriformis muscle, one case 
of transient numbness lasting no longer than 72 h) [6]. 
Michel and colleagues demonstrated the efficacy of BoNT-A administration into piriformis muscle 
in 122 subjects who were previously treated with medication and rehabilitation protocols with no pain 
improvement [16]. A dose of onabotulinumtoxin A between 50 and 100 U was injected under guidance 
with EMG. The minimum interval between injections was 3 months. A group of 51 patients received 
one single injection, 43 subjects had two injections, 18 had three injections, nine had four injections, 
and only one had five injections. The average interval was 18 weeks between the first and second 
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injections, 31 weeks between second and third injections, 45 weeks between third and fourth injections, 
and 57 weeks between fourth and the fifth injections. The patients injected have been evaluated using 
the VAS: Pain relief was ‘very good’ or ‘good’ in 77% of the cases, ‘average’ in 7.4% and ‘poor’ in 
15.6% of the cases. No adverse events have been reported. 
The important role of instrumental guidance to inject piriformis muscle has been described also by 
Fabregat and colleagues [18] that demonstrated the effectiveness of ultrasound (US)-guided procedure 
to identify the muscle injecting 10 patients suffering from PMS with 100 U of onabotulinumtoxin A 
reconstituted with normal saline for a total volume of 5 mL [18]. Furthermore, in a single-centre,  
case-control study conducted by Al-Al-Shaikh and colleagues, the authors described the changes in the 
piriformis muscle morphology induced by onabotulinumtoxin A 100 U administered into the 
piriformis muscle (10 subjects) under US guide and into piriformis muscle and obturator internus 
muscles (2 subjects) under CT guidance. The authors reported a significant difference on VAS in terms 
of buttock pain and sciatic pain before and after treatment [19]. Finally, another serotype of botulinum 
toxin can be used to reduce muscle pain. In fact, a study showed the safety and the effectiveness of 
physical therapy and 12,500 units of BoNT-B administered under EMG-guidance in 27 subjects 
suffering from PMS, for more than 3 months [20], whereas Lang evaluated the clinical safety and 
efficacy of 5000 U of BoNT-B under EMG-guidance in 20 patients with PMS, demonstrating a 
reduction of myofascial pain associated with this syndrome [21]. In these studies with BoNT-B in 
PMS, the most severe adverse effects were dry mouth and dysphagia, approaching 50% of patients at 
two and four weeks in the first report [20] and dry mouth reported in six of 20 patients in the report of 
Lang [21]. 
4. Case Report 
In this report, we described the case of a 55-years-old man with right buttock and leg pain  
exacerbated by the sitting position and hip extra-rotation. Pain affected everyday activities including 
his job. In fact, the patient was a driver and he needed to spend much time sitting. Physiatric  
examination revealed no neurologic signs of lumbar herniatic disc or spinal cord compression. These 
clinical findings were confirmed by instrumental diagnostic investigations. The magnetic resonance 
imaging (MRI) did not show any vertebral alterations and no neurogenic muscle atrophy or sciatic and 
femoral nerves damage was detected by EMG. Hip radiographs excluded any orthopedic cause of pain. 
A trigger point was identified by palpation of the right buttock with pain radiating down the thigh. 
Considering these symptoms, a PMS was suspected. Specific tests were performed to validate the  
diagnosis. In particular, the FAIR test was applied downward pressure to the symptomatic flexed knee 
while maximizing the adduction and internal rotation in the symptomatic flexed hip in the lateral  
decubitus position [22], and Freiberg’s maneuver was performed with patient in supine position and 
rotating internally the extended thigh on the affected side [23]. Finally, Pace’s maneuver, actively  
abducting both thighs against resistance in the seated position was done [24]. All these tests were  
positive. A US-guided injection of local anesthetic into the piriformis muscle was performed.  
The marked and immediate relief of pain confirmed the diagnosis of PMS [25]. 
The active articular ROM of the coxo-femoral joint was limited by pain with an extra-rotation of 20°, 
abduction of 25° and extension of 10°. Pain score was measured using the VAS [26]. VAS score in 
sitting position was 9/10. The patient was initially treated with oral drugs (muscle relaxant and  
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anti-inflammatory medications, benzodiazepines), physical therapies (high-intensity laser therapy,  
diatermia, and US therapy), hip and thigh mobilization, gluteus muscles massages in order to reduce 
piriformis muscle spasm and contracture. No benefits were observed after these treatments. A botulinum 
neurotoxin therapy was then started. This decision was taken according to previous studies [3,4,6,16–21] 
(Table 1).  
The patient was placed in a prone position. The method of locating the sciatic nerve as proposed by 
Smith and colleagues was adopted [27]. The B-mode real-time ultrasonography was performed using 
the MyLab 70 XV (Esaote, Genova, Italy) with a linear transducer (scanning frequency, 6–18 MHz) to 
guide the needle positioning into the targeted muscle. The transducer was positioned in the transverse 
view, perpendicular to the gluteus maximus muscle. The probe was initially positioned with its lateral 
side medial to the greater trochanter and then with its medial side lateral to the ischial tuberosity 
(Figure 1). The piriformis muscle was identified between gluteal muscles and ischial spine (Figure 2). 
The patient was treated with incobotulinumtoxin A, using a 22 gauge (0.70 × 90 mm) spinal needle, 
injecting the right piriformis muscle into one point with a dose of 40 U with 2 cc of saline dilution. 
The procedure was well tolerated and no adverse effects were noted. No additional treatments were 
performed.  
(a) (b) 
Figure 1. Positioning of the probe initially with its lateral side medial to the greater 
trochanter (a) and finally positioned with its medial side lateral to the ischial tuberosity (b). 
A few days after the treatment, the patient reported a significant regression of most signs and 
symptoms, in terms of pain (VAS score: 2/10) and functional outcome: The range of hip external 
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rotation was significantly higher and ranged to 45°, as well as abduction and extension movements, 
respectively 40° and 20°. Quality of life and work also improved, the patient was able to spend more 
time sitting and could easily get in and out of the car; extra rotating his hip with no pain. In the eighth 
month of follow up, the positive effect of BoNT-A injection into piriformis muscle was still present. 
 
Figure 2. Ultrasound identification of the piriformis muscle between gluteus maximus 
muscle and ischial spine. 
5. Discussion 
In the present report, we described a case of PMS treated with BoNT-A in a 55-years-old man who 
referred a right buttock and leg pain exacerbated with sitting position and hip extra-rotation.  
The absence of radicular signs for lumbar hernia or spinal cord compression as well as the reduction of 
pain after a local piriformis muscle anesthetic injection under US guidance, confirmed the diagnosis.  
PMS is a common cause of muscle pain secondary to piriformis contracture with sciatic nerve  
impairment. As described by Stewart, four pathological conditions can be identified: damage to the 
proximal sciatic nerve by lesions in the vicinity of the piriformis; compression damage to the proximal 
sciatic nerve by the piriformis; damage to the sciatic nerve by the piriformis; and adjacent tissues from 
trauma and scarring and chronic buttock pain with no evidence of sciatic nerve damage [28]. BoNT 
injections have been used to treat muscle and myofascial pain in several studies [10–12]. Muscle pain 
Toxins 2015, 7 3053 
 
in PMS can be evoked by a chemical C and A fibers stimulation because of local production of lactate 
and acid PH induced by long-term contracture and ischemia related. The reduction of muscle 
contracture obtained by BoNT-A or BoNT-B injections may explain the pain decrease. Moreover, 
BoNT-A has been found to inhibit bradykinins, serotonin, potassium, prostaglandin E2, substance P 
and the neuropeptide CGRP reducing sensitization of muscle nociceptors [13–15]. For this reason, 
BoNT-A can be used, as well as steroid methylprednisolone with bupivacaine, to treat myofascial pain 
syndrome and pain from chronic muscle spasm [29].  
However, treatment effectiveness is strictly related to injection accuracy, reducing also, especially 
using anesthetic drug, the risk of sciatic nerve sensorimotor block. In fact considering the difficult 
access of the needle for deep location, the small size of the muscle, the proximity to neurovascular 
structures, and the possibility of anomalous sciatic nerve and piriformis arrangement, several 
techniques of piriformis injections have been proposed and described: CT, MRI, US, fluoroscopy, 
electrical stimulators, or EMG [3,4,6,16–21,30–36]. Nerve stimulator and anatomic landmarks have 
been proposed by Hanania and colleagues [30,31]. Fishman and colleagues described a technique 
using EMG to confirm a correct needle placement correlating with the fluoroscopic image [32].  
Betts described the use electrical muscle stimulation to better define the location of the piriformis 
muscle and the fluoroscopy helped to ensure precise needle placement for an accurate injection [33], 
whereas Gonzalez and colleagues did not use electrical stimulation but anatomic landmarks and 
fluoroscopic guidance to document the needle placement within the piriformis muscle of a cadaveric 
specimen [34]. Ultrasonography is well established as a reliable and reproducible imaging method in 
muscle anatomy, and several studies have shown applicability of the procedure for visually-controlled 
BoNT-A injection [35]. Smith and colleagues confirmed the advantages of US-guided piriformis 
injection technique, considering accessibility, compact size, lack of ionizing radiation exposure, and 
direct visualization of neurovascular structures [27]. In conclusion, the findings of the present case 
report are similar to those of previous studies on this topic [3,4,6,16–21] (Table 1). After 
incobotulinumtoxin A injection, the buttock and posterior hip pain was drastically reduced improving 
hip functionality and quality of work and life. BoNT-A may be an agent suitable for PMS. On the 
other hand, a recent Cochrane review, found that BoNT injections were better than injections of 
corticosteroid plus lidocaine, or traditional acupuncture or placebo in patients with sciatica attributed 
to PMS [36]. Instrumental guidance of injections is necessary to avoid the BoNT spreading to 
neurovascular structures. In the future, careful blinded US-guided studies in a larger number of 
patients are needed to establish the efficacy of BoNT injections in PMS. 
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